Search by Drug Name or NDC

    NDC 45963-0614-55 Irinotecan hydrochloride 20 mg/mL Details

    Irinotecan hydrochloride 20 mg/mL

    Irinotecan hydrochloride is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Actavis Pharma, Inc.. The primary component is IRINOTECAN HYDROCHLORIDE.

    Product Information

    NDC 45963-0614
    Product ID 45963-614_ddf510c7-0652-4cb7-93aa-67510de8ac61
    Associated GPIs 21550040102025 21550040102030
    GCN Sequence Number 062173
    GCN Sequence Number Description irinotecan HCl VIAL 40 MG/2 ML INTRAVEN
    HIC3 V3E
    HIC3 Description ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS
    GCN 97955
    HICL Sequence Number 010778
    HICL Sequence Number Description IRINOTECAN HCL
    Brand/Generic Generic
    Proprietary Name Irinotecan hydrochloride
    Proprietary Name Suffix n/a
    Non-Proprietary Name Irinotecan hydrochloride
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 20
    Active Ingredient Units mg/mL
    Substance Name IRINOTECAN HYDROCHLORIDE
    Labeler Name Actavis Pharma, Inc.
    Pharmaceutical Class Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA078589
    Listing Certified Through 2024-12-31

    Package

    NDC 45963-0614-55 (45963061455)

    NDC Package Code 45963-614-55
    Billing NDC 45963061455
    Package 1 VIAL, SINGLE-DOSE in 1 CARTON (45963-614-55) / 5 mL in 1 VIAL, SINGLE-DOSE
    Marketing Start Date 2015-03-12
    NDC Exclude Flag N
    Pricing Information N/A